Loading...
XSHG
688266
Market cap4.13bUSD
Dec 05, Last price  
110.34CNY
1D
-0.88%
1Q
-8.69%
IPO
65.28%
Name

Suzhou Zelgen Biopharmaceuticals Co Ltd

Chart & Performance

D1W1MN
XSHG:688266 chart
P/E
P/S
54.80
EPS
Div Yield, %
Shrs. gr., 5y
2.01%
Rev. gr., 5y
211.81%
Revenues
533m
+37.91%
200,33401,311,158027,660,909190,360,565302,305,057386,438,784532,954,371
Net income
-138m
L-50.52%
0000000-278,582,744-137,830,775
CFO
38m
P
0000000-220,313,12138,204,544

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Suzhou Zelgen Biopharmaceuticals Co., Ltd. researches and develops, manufactures, and sells medicines in the People's Republic of China. It offers small molecule and recombinant protein drugs for the treatment of liver cancer, non-small cell lung cancer, colorectal cancer, thyroid cancer, nasopharyngeal carcinomas, myelofibrosis, hemorrhage, and hepatobiliary diseases. The company was founded in 2009 and is based in Kunshan, the People's Republic of China.
IPO date
Jan 23, 2020
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT